Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samy Suissa

Showing results (11-20 of 444) with videos related to

Pageof 45
Sort By:
American Journal of Epidemiology|June 3, 2008
Immeasurable time bias in observational studies of drug effects on mortalitySamy Suissa
ERJ Open Research|February 2, 2023
Triple therapy in COPD: understanding the dataSamy Suissa
Respiration; International Review of Thoracic Diseases|June 17, 2010
Co-morbidity in COPD: the effects of cardiovascular drug therapiesSamy Suissa
The European Respiratory Journal|December 14, 2023
Simplifying pharmacotherapy for patients with COPD: a viewpointSamy Suissa
American Journal of Respiratory and Critical Care Medicine|May 11, 2004
Inhaled corticosteroids in COPD and mortality: inaccuracies?Samy Suissa
Diabetes Care|May 23, 2018
Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10Samy Suissa
Circulation|April 4, 2018
Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time BiasSamy Suissa
The European Respiratory Journal|April 2, 2015
Number needed to treat: enigmatic results for exacerbations in COPDSamy Suissa
The New England Journal of Medicine|September 4, 2014
Simvastatin in moderate-to-severe COPDSamy Suissa
Chest|July 10, 2024
COUNTERPOINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? NoSamy Suissa
Pageof 45

Showing results (11-20 of 444) with videos related to

Sort By:
Pageof 45
American Journal of Epidemiology|June 3, 2008
Immeasurable time bias in observational studies of drug effects on mortalitySamy Suissa
ERJ Open Research|February 2, 2023
Triple therapy in COPD: understanding the dataSamy Suissa
Respiration; International Review of Thoracic Diseases|June 17, 2010
Co-morbidity in COPD: the effects of cardiovascular drug therapiesSamy Suissa
The European Respiratory Journal|December 14, 2023
Simplifying pharmacotherapy for patients with COPD: a viewpointSamy Suissa
American Journal of Respiratory and Critical Care Medicine|May 11, 2004
Inhaled corticosteroids in COPD and mortality: inaccuracies?Samy Suissa
Diabetes Care|May 23, 2018
Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10Samy Suissa
Circulation|April 4, 2018
Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time BiasSamy Suissa
The European Respiratory Journal|April 2, 2015
Number needed to treat: enigmatic results for exacerbations in COPDSamy Suissa
The New England Journal of Medicine|September 4, 2014
Simvastatin in moderate-to-severe COPDSamy Suissa
Chest|July 10, 2024
COUNTERPOINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? NoSamy Suissa
Pageof 45